Single Intravascular and Oral Dose Pharmacokinetics of Mebendazole in Blunt Snout Bream, Megalobrama amblycephala

Mebendazole (MBZ) is a broad-spectrum benzimidazole methylcarbamate anthelmintic used widely in animal husbandry and aquaculture. However, there is no information available on the pharmacokinetic behavior of MBZ in blunt snout bream, Megalobrama amblycephala. In this study, pharmacokinetic parameters of MBZ were estimated in blunt snout bream after intravascular (3mg/kg body weight [BW]) and oral (20mg/kg BW) administration. The analyses of plasma samples were performed using ultra performance liquid chromatography with ultraviolet detector. After intravascular administration, plasma concentration-time curves were best described by a two-compartment open model. The distribution half-life (t(1/2)), elimination half-life (t(1/2)), and area under the concentration-time curve (AUC) of blunt snout bream were 0.1h, 27.9h, and 56666.0h.mu g/L, respectively. After oral administration, a one-compartment open model with first-order absorption best fit the plasma data. The absorption half-life (t(1/2Ka)), elimination half-life (t(1/2Ke)), peak concentration (C-max), time-to-peak concentration (T-max), and AUC of blunt snout bream were estimated to be 1.9 h, 34.6 h, 918.1 mu g/L, 8.4 h, and 54201.4 h.mu g/L, respectively. The oral bioavailability (F) was 14.3 %. The pharmacokinetics of MBZ in blunt snout bream displayed low bioavailability, relatively rapid absorption, and relatively rapid elimination.